)
Henry Schein (HSIC) investor relations material
Henry Schein Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategy and business mix
Over 50% of income targeted from high-growth, high-margin products by 2027; expected to exit 2026 at that rate, with mix shift continuing.
Dental market share gains and value-creation actions are supporting operating-income expansion; technology capabilities are building a broader customer-support platform.
Dentrix Ascend and Dentally are gaining cloud placements and share of wallet; specialty growth includes implants in Europe and value implants in the U.S.
S.I.N. 360 is launching new products, supporting continued mix shift toward higher-growth, higher-margin businesses.
Market conditions and pricing
Market conditions described as steady, with patient traffic tied more to employment and insurance than consumer sentiment; exposure to discretionary procedures is limited.
New pricing people, tools and systems are improving visibility, enabling targeted price increases where value supports them and reductions where needed to compete and gain share.
Supplier price increases and inflation continue to be passed on appropriately; private-label and own-brand options help address value needs and inflation.
DSO growth is viewed positively, with lower service costs and formulary adoption supporting the model; private-practice growth also improved sequentially from Q1 to Q2 and Q2 to Q3.
Equipment and technology
Q4 equipment orders showed sequential and YoY growth; traditional equipment was growing, while digital equipment had volume growth but not revenue growth amid lower-priced entrants.
Digital equipment adoption can lift merchandise sales through higher practice productivity.
Technology growth was ~8% this year, with a potential 8%-12% growth rate; drivers include new cloud placements, package upgrades and additional capabilities.
Cloud platforms added ~200 installations per month; AI capabilities, including those developed by other providers, are being brought onto the platform to improve practice productivity.
- FY2025 sales grew 4%, with a 2027 target to source over half of non-GAAP operating income from high-growth businesses.HSIC
Corporate presentation - Q3 sales rose 4%, adjusted EPS grew 19.1%, and FY2026 EPS guidance increased.HSIC
Q3 2026 - Growth acceleration, operational rigor, and disciplined capital allocation drive strong performance.HSIC
2026 Global Healthcare Conference - Global leader in dental and medical products with $13.2B sales and strong growth momentum.HSIC
Corporate presentation - Q2 2026 saw strong sales, margin gains, and raised guidance, with robust segment growth.HSIC
Q2 2026 - Lowery’s appointment, share gains and a $200M+ plan underpin growth and BOLD+1 execution.HSIC
44th Annual J.P. Morgan Healthcare Conference - Record Q3 2025 results, raised guidance, and $200M+ value creation initiatives announced.HSIC
Q3 2025 - Q2 2024 sales up 1.1% to $3.14B; net income and EPS declined, and guidance was reduced.HSIC
Q2 2024 - Q4 2024 non-GAAP EPS rose 80% on 5.8% sales growth; 2025 outlook targets steady gains.HSIC
Q4 2024
)
)
)
)
)
)
)
)